These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35099760)

  • 1. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
    Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study.
    Kitticharoenjit P; Supakul N; Rujkijyanont P; Traivaree C; Photia A; Monsereenusorn C
    Asian Biomed (Res Rev News); 2021 Aug; 15(4):171-181. PubMed ID: 37551332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis.
    Minkov M; Pötschger U; Thacker N; Astigarraga I; Braier J; Donadieu J; Henter JI; Lehrnbecher T; Rodriguez-Galindo C; Sieni E; Nanduri V; van den Bos C; Abla O;
    J Pediatr; 2021 Oct; 237():65-70.e3. PubMed ID: 34146548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
    Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
    Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: A single-center, 20-year experience.
    Wang DS; Lu MY; Yang YL; Lin DT; Lin KH; Chang HH; Jou ST
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):594-601. PubMed ID: 32741735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
    Wu FF; Gao YJ; Pan C; Chen J; Tang JY
    Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood.
    Aricò M; Astigarraga I; Braier J; Donadieu J; Gadner H; Glogova E; Grois N; Henter JI; Janka G; McClain KL; Ladisch S; Pötschger U; Rosso D; Thiem E; Weitzman S; Windebank K; Minkov M;
    Br J Haematol; 2015 Apr; 169(2):241-8. PubMed ID: 25522229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
    İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
    Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis.
    Monsereenusorn C; Suwannaying K; Buaboonnam J; Sathitsamitphong L; Techavichit P; Pakakasama S; Chainansamit SO; Anurathapan U; Komvilaisak P; Traivaree C; Sanpakit K; Charoenkwan P; Seksarn P
    Asian Pac J Cancer Prev; 2024 May; 25(5):1831-1839. PubMed ID: 38809656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.